Kairos Pharma reports positive Phase 2 interim PFS data
Kairos Pharma announced statistically significant Phase 2 interim efficacy results for ENV-105 plus apalutamide, showing a median PFS of 17.7 months compared to 2 months for apalutamide alone, with a P-value of 0.0008.
Key Highlights:Original SEC Filing: Kairos Pharma, LTD. [ KAPA ] - 8-K - Oct. 06, 2026This is an AI-powered summary. It may c…